{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:47:56Z","timestamp":1761961676517,"version":"build-2065373602"},"reference-count":57,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1053\/j.seminhematol.2010.06.007","type":"journal-article","created":{"date-parts":[[2010,9,29]],"date-time":"2010-09-29T05:04:19Z","timestamp":1285736659000},"page":"327-334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Practical Considerations for Monitoring Patients With Chronic Myeloid Leukemia"],"prefix":"10.1053","volume":"47","author":[{"given":"Susan","family":"Branford","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy P.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2010.06.007_bib1","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/cncr.20922","article-title":"Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up","volume":"103","author":"Lahaye","year":"2005","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2010.06.007_bib2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/10428190500353133","article-title":"Fluorescent in situ hybridization in the diagnosis, prognosis, and treatment monitoring of chronic myeloid leukemia","volume":"47","author":"Landstrom","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2010.06.007_bib3","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1182\/blood-2009-07-229864","article-title":"Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP","volume":"114","author":"Testoni","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.007_bib4","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol."},{"key":"10.1053\/j.seminhematol.2010.06.007_bib5","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/sj.leu.2403604","article-title":"e8a2 BCR-ABL: more frequent than other atypical BCR-ABL variants?","volume":"19","author":"Demehri","year":"2005","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.06.007_bib6","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.007_bib7","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.007_bib8","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/leu.2009.168","article-title":"Harmonization of molecular monitoring of CML therapy in Europe","volume":"23","author":"Muller","year":"2009","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.06.007_bib9","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.beha.2009.04.001","article-title":"Standardisation of molecular monitoring for chronic myeloid leukaemia","volume":"22","author":"Cross","year":"2009","journal-title":"Best Pract Res Clin Haematol."},{"key":"10.1053\/j.seminhematol.2010.06.007_bib10","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/leu.2008.330","article-title":"Reply to \u2018What do we mean by sensitivity when we talk about detecting minimal residual disease?'","volume":"23","author":"Ross","year":"2008","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.06.007_bib11","first-page":"S49","article-title":"Limit of blank, limit of detection and limit of quantitation","volume":"29","author":"Armbruster","year":"2008","journal-title":"Clin Biochem Rev."},{"key":"10.1053\/j.seminhematol.2010.06.007_bib12","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood.V92.9.3362","article-title":"The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease","volume":"92","author":"Bose","year":"1998","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.007_bib13","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2141.1999.01749.x","article-title":"Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics","volume":"107","author":"Branford","year":"1999","journal-title":"Br J Haematol."},{"key":"10.1053\/j.seminhematol.2010.06.007_bib14","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.007_bib15","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia\u2014a Europe Against Cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.06.007_bib16","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.1158\/1078-0432.CCR-07-0844","volume":"13","author":"Branford","year":"2007","journal-title":"Clin Cancer Res."},{"key":"10.1053\/j.seminhematol.2010.06.007_bib17","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2141.2009.07646.x","article-title":"Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?","volume":"145","author":"Marin","year":"2009","journal-title":"Br J Haematol."},{"key":"10.1053\/j.seminhematol.2010.06.007_bib18","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1158\/1078-0432.CCR-07-1112","article-title":"A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response","volume":"13","author":"Press","year":"2007","journal-title":"Clin Cancer Res."},{"key":"10.1053\/j.seminhematol.2010.06.007_bib19","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/cncr.23238","article-title":"Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?","volume":"112","author":"Kantarjian","year":"2008","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2010.06.007_bib20","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol."},{"key":"10.1053\/j.seminhematol.2010.06.007_bib21","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","article-title":"Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?","volume":"114","author":"Branford","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.007_bib22","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1182\/blood-2004-03-1134","article-title":"Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations","volume":"104","author":"Branford","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.007_bib23","first-page":"235","article-title":"The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia","volume":"91","author":"Wang","year":"2006","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2010.06.007_bib24","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1182\/blood-2008-08-173674","article-title":"Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib","volume":"114","author":"Press","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.007_bib25","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.007_bib26","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mmutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol."},{"key":"10.1053\/j.seminhematol.2010.06.007_bib27","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations","volume":"114","author":"Muller","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.007_bib28","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency","volume":"117","author":"Shah","year":"2007","journal-title":"J Clin Invest."},{"key":"10.1053\/j.seminhematol.2010.06.007_bib29","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood-2009-01-197186","article-title":"Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors","volume":"114","author":"Soverini","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.007_bib30","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants","volume":"27","author":"Redaelli","year":"2009","journal-title":"J Clin Oncol."},{"key":"10.1053\/j.seminhematol.2010.06.007_bib31","article-title":"Detection of drug-resistant clones in chronic myelogenous leukemia patients during dasatinib and nilotinib treatment","author":"Gruber","year":"2009","journal-title":"Clin Chem."},{"key":"10.1053\/j.seminhematol.2010.06.007_bib32","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood-2005-03-1036","article-title":"High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy","volume":"106","author":"Willis","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.007_bib33","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nature07943","article-title":"The cancer genome","volume":"458","author":"Stratton","year":"2009","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2010.06.007_bib34","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.V100.3.1014","article-title":"Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment","volume":"100","author":"Roche-Lestienne","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.007_bib35","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/asheducation-2007.1.384","article-title":"The biology of CML blast crisis","volume":"2007","author":"Radich","year":"2007","journal-title":"Hematology"},{"key":"10.1053\/j.seminhematol.2010.06.007_bib36","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/sj.leu.2403935","article-title":"A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib","volume":"19","author":"Crossman","year":"2005","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.06.007_bib37","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3324\/haematol.12964","article-title":"ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia","volume":"93","author":"Ernst","year":"2008","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2010.06.007_bib38","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/sj.leu.2404400","article-title":"A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib","volume":"20","author":"Gruber","year":"2006","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.06.007_bib39","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/leu.2008.65","article-title":"Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia","volume":"22","author":"Sherbenou","year":"2008","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.06.007_bib40","first-page":"93","article-title":"Detection of BCR-ABL mutations and resistance to imatinib mesylate","volume":"Vol. 125","author":"Branford","year":"2006"},{"key":"10.1053\/j.seminhematol.2010.06.007_bib41","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2353\/jmoldx.2008.070128","article-title":"An intron-derived insertion\/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy","volume":"10","author":"Laudadio","year":"2008","journal-title":"J Mol Diagn."},{"key":"10.1053\/j.seminhematol.2010.06.007_bib42","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2353\/jmoldx.2008.080055","article-title":"ABL kinase domain pseudoexon insertion is not uncommon in BCR-ABL transcripts","volume":"10","author":"Quigley","year":"2008","journal-title":"J Mol Diagn."},{"key":"10.1053\/j.seminhematol.2010.06.007_bib43","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1158\/1535-7163.MCT-08-0482","article-title":"BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations","volume":"7","author":"Lee","year":"2008","journal-title":"Mol Cancer Ther."},{"key":"10.1053\/j.seminhematol.2010.06.007_bib44","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","article-title":"Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients","volume":"22","author":"Peng","year":"2004","journal-title":"J Clin Oncol."},{"key":"10.1053\/j.seminhematol.2010.06.007_bib45","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.007_bib46","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.007_bib47","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.leukres.2008.07.015","article-title":"Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels","volume":"33","author":"Forrest","year":"2009","journal-title":"Leuk Res."},{"key":"10.1053\/j.seminhematol.2010.06.007_bib48","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.beha.2009.09.007","article-title":"Pharmacologic monitoring and determinants of intracytoplasmic drug levels","volume":"22","author":"Mahon","year":"2009","journal-title":"Best Pract Res Clin Haematol."},{"key":"10.1053\/j.seminhematol.2010.06.007_bib49","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity","volume":"110","author":"White","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.007_bib50","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/sj.clpt.6100268","article-title":"Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia","volume":"83","author":"Wang","year":"2008","journal-title":"Clin Pharmacol Ther."},{"key":"10.1053\/j.seminhematol.2010.06.007_bib51","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1200\/JCO.2006.09.9499","article-title":"Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia","volume":"25","author":"White","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1053\/j.seminhematol.2010.06.007_bib52","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood-2008-03-147744","article-title":"Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"112","author":"Dulucq","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.007_bib53","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1182\/blood-2009-03-212969","article-title":"The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data","volume":"114","author":"Oehler","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.007_bib54","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1200\/JCO.2008.19.4076","article-title":"Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance","volume":"27","author":"Zhang","year":"2009","journal-title":"J Clin Oncol."},{"key":"10.1053\/j.seminhematol.2010.06.007_bib55","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1182\/blood-2009-03-210732","article-title":"A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib","volume":"115","author":"McWeeney","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.007_bib56","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/blood-2005-05-2155","article-title":"Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML","volume":"107","author":"Yong","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.007_bib57","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.leu.2404227","article-title":"Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis","volume":"20","author":"Zheng","year":"2006","journal-title":"Leukemia"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196310000818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196310000818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:20:42Z","timestamp":1758522042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196310000818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0037196310000818"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.06.007","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Practical Considerations for Monitoring Patients With Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown copyright \u00a9 2010 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}